{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T11:15:23Z","timestamp":1776510923749,"version":"3.51.2"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Fluoroquinolones (FQs) are associated with adverse effects and increasing resistance. However, uncomplicated cystitis remains a frequent reason for FQ use. Selective reporting involves withholding susceptibilities for select antimicrobial agents on microbiology reports, in hopes of dissuading use by providers. The purpose of this study was to investigate the impact of FQ susceptibility suppression on discharge prescribing for hospitalized patients with uncomplicated cystitis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective quasi-experimental analysis was conducted among adult patients at a 350-bed academic medical center. Its aim was to compare the incidence of FQ prescribing for cystitis at hospital discharge, one year before and after implementation (1 March 2017\u201331 March 2019) of a policy to suppress FQ urinary susceptibility results for pansusceptible Klebsiella spp and Escherichia coli. FQ appropriateness and risk factors for FQ use were also examined.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There was a relative risk reduction of 39% in discharge FQ prescribing when adjusted for discharge team (adjusted risk ratio, 0.61; 95% CI, .40\u2013.93). Almost all FQ use was inappropriate, largely due to organisms\u2019 susceptibility to a guideline-preferred agent (n = 61). In multivariate analysis, odds ratios of discharge FQ prescribing were 0.22 (95% CI, .12\u2013.39) for insured patients, 0.43 (95% CI, .21\u2013.86) for patients with antibiotic allergy, and 57.8 (95% CI, 13.7\u2013244) for those receiving inpatient FQ. Discharge from a medicine team was protective against discharge FQ prescribing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>With multidisciplinary inpatient medicine services and avoidance of inpatient FQ use, suppression of FQ susceptibilities on pansusceptible urine isolates for Klebsiella spp and E coli may represent an attractive strategy for antibiotic stewardship at hospital discharge.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofad459","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T09:30:22Z","timestamp":1694165422000},"source":"Crossref","is-referenced-by-count":6,"title":["Impact of Fluoroquinolone Susceptibility Suppression on Discharge Prescribing for Acute Uncomplicated Cystitis"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1058-9464","authenticated-orcid":false,"given":"Dillon A","family":"Hayden","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Oklahoma Medical Center , Oklahoma City, Oklahoma , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan P","family":"White","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Oklahoma , Oklahoma City, Oklahoma , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Neely","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Oklahoma , Oklahoma City, Oklahoma , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiya K","family":"Bennett","sequence":"additional","affiliation":[{"name":"Department of Clinical and Administration Sciences, College of Pharmacy, University of Oklahoma , Oklahoma City, Oklahoma , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"key":"2023101617160683600_ofad459-B1","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2023101617160683600_ofad459-B2","doi-asserted-by":"crossref","first-page":"e02072-18","DOI":"10.1128\/JCM.02072-18","article-title":"Don\u2019t get wound up: revised fluoroquinolone breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa","volume":"57","author":"Van","year":"2019","journal-title":"J Clin Microbiol"},{"key":"2023101617160683600_ofad459-B3","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ajem.2014.04.033","article-title":"Resistance of Escherichia coli urinary isolates in ED-treated patients from a community hospital","volume":"32","author":"Fleming","year":"2014","journal-title":"Am J Emerg Med"},{"key":"2023101617160683600_ofad459-B4","article-title":"FDA updates warnings for fluoroquinolone antibiotics on risks of mental health and low blood sugar adverse reactions","author":"US Food and Drug Administration","year":"2018"},{"key":"2023101617160683600_ofad459-B5","doi-asserted-by":"crossref","first-page":"ofab538","DOI":"10.1093\/ofid\/ofab538","article-title":"Ambulatory fluoroquinolone use in the United States, 2015\u20132019","volume":"8","author":"Umarje","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2023101617160683600_ofad459-B6","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1001\/jamainternmed.2021.1154","article-title":"Association of US food and drug administration removal of indications for use of oral quinolones with prescribing trends","volume":"181","author":"Tran","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2023101617160683600_ofad459-B7","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1017\/ice.2019.293","article-title":"Nudging in MicroBiology Laboratory Evaluation (NIMBLE): a scoping review","volume":"40","author":"Langford","year":"2019","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2023101617160683600_ofad459-B8","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1093\/cid\/ciw118","article-title":"Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America","volume":"62","author":"Barlam","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2023101617160683600_ofad459-B9","first-page":"1","article-title":"The association of antibiotic stewardship with fluoroquinolone prescribing in Michigan hospitals: a multi-hospital cohort study","volume":"iy102","author":"Vaughn","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023101617160683600_ofad459-B10","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/cid\/ciab842","article-title":"Antibiotic overuse and stewardship at hospital discharge: the reducing overuse of antibiotics at discharge home framework","volume":"74","author":"Vaughn","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023101617160683600_ofad459-B11","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1017\/ash.2021.178","article-title":"Impact of suppressing ciprofloxacin susceptibility results on antibiotic utilization and hospital-acquired Clostridioides difficile infection","volume":"1","author":"White","year":"2021","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"key":"2023101617160683600_ofad459-B12","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/jac\/dkg032","article-title":"Laboratory antibiotic susceptibility reporting and antibiotic prescribing in general practice","volume":"51","author":"Tan","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2023101617160683600_ofad459-B13","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/jac\/dkr088","article-title":"Does laboratory antibiotic susceptibility reporting influence primary care prescribing in urinary tract infection and other infections?","volume":"66","author":"McNulty","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2023101617160683600_ofad459-B14","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/cid\/ciab987","article-title":"Optimal urine culture diagnostic stewardship practice\u2014results from an expert modified-Delphi procedure","volume":"75","author":"Claeys","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023101617160683600_ofad459-B15","article-title":"Performance standards for antimicrobial susceptibility testing; 29th informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2019"},{"key":"2023101617160683600_ofad459-B16","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/bjsm.2008.054734","article-title":"QTc: how long is too long?","volume":"43","author":"Johnson","year":"2009","journal-title":"Br J Sports Med"},{"key":"2023101617160683600_ofad459-B17","article-title":"Oklahoma high on uninsured list","author":"Sweeney","year":"2018","journal-title":"Journal Record"},{"key":"2023101617160683600_ofad459-B18","first-page":"251","article-title":"RCPAQAP audit of antimicrobial reporting in Australian and New Zealand laboratories: opportunities for laboratory contribution to antimicrobial stewardship","volume":"74","author":"Graham","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023101617160683600_ofad459-B19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ijantimicag.2016.11.014","article-title":"Selective reporting of antibiotic susceptibility test results in European countries: an ESCMID cross-sectional survey","volume":"49","author":"Pulcini","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2023101617160683600_ofad459-B20","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1128\/JCM.00950-16","article-title":"Antimicrobial stewardship in the microbiology laboratory: impact of selective susceptibility reporting on ciprofloxacin utilization and susceptibility of gram negative isolates to ciprofloxacin in a hospital setting","volume":"54","author":"Langford","year":"2016","journal-title":"J Clin Microbiol"},{"key":"2023101617160683600_ofad459-B21","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/jama.2017.6510","article-title":"Penicillin allergy is not necessarily forever","volume":"318","author":"Trubiano","year":"2017","journal-title":"JAMA"},{"key":"2023101617160683600_ofad459-B22","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/all.12881","article-title":"Drug allergies documented in electronic health records of a large healthcare system","volume":"71","author":"Zhou","year":"2016","journal-title":"Allergy"},{"key":"2023101617160683600_ofad459-B23","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jgs.15767","article-title":"American Geriatrics Society 2019 updated AGS Beers Criteria for potentially inappropriate medication use in older adults","volume":"67","author":"Beers Criteria Update Expert Panel","year":"2019","journal-title":"J Am Geriatr Soc"},{"key":"2023101617160683600_ofad459-B24","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1017\/ice.2021.520","article-title":"Antimicrobial stewardship intervention bundle decreases outpatient fluoroquinolone prescribing for urinary tract infections","volume":"44","author":"Cubillos","year":"2023","journal-title":"Infect Control Hosp Epidemiol"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofad459\/51439662\/ofad459.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/10\/ofad459\/52173472\/ofad459.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/10\/ofad459\/52173472\/ofad459.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T18:03:11Z","timestamp":1697479391000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofad459\/7264042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofad459","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,9,8]]},"article-number":"ofad459"}}